secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2026-03-16T23:59:59+00:00
Accession:  0001193125-26-108344
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Atara reports FY 2025 net income of $32.7M; cash runway extended through YE 2026
--------------------------------------------------------------------------------

- Net income of $32.7M ($2.61 per share) in FY 2025 vs. net loss of $85.4M in FY 2024.
- Cash, equivalents and investments $8.5M at Dec 31, 2025; net cash used in ops $50.9M in FY 2025.
- Operating expenses declined sharply; expects cash plus $3.0M ATM proceeds to fund ops through YE 2026.
- Pierr Fabre scheduled FDA Type A meeting for tab-cel PTLD; regulatory update expected in Q2 2026.
- Milestone payment of $9.0M due to HCRx deferred from June 2026 to Jan 2028; warrant issued for 400K shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/0001193125-26-108344-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312526108344/atra-20260316.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-108344

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer